沙利度胺治疗不同类型红斑狼疮皮损的疗效观察

Clinical observation of thalidomide in treating different types of cutaneous lesionsof lupus erythematosus

目的:观察沙利度胺(thalidomide)对不同类型红斑狼疮(LE)皮肤损害的临床疗效。方法:选择56例不同类型的LE患者,包括慢性皮肤型红斑狼疮(CCLE)19例,深部红斑狼疮(LEP)2例,红斑狼疮-扁平苔藓综合征(LE-LP)2例,亚急性皮肤型红斑狼疮(SCLE)7例和系统性红斑狼疮(SLE)26例。患者口服沙利度胺,初始剂量为100～150mg/d,2周后根据疗效反应酌情减量,最后维持量为12.5～25mg/d;疗程6～8个月。结果:各型LE患者的皮肤损害均对沙利度胺有良好反应,56例中有41例皮损痊愈,近期治愈率达73.2%,复发率为21.9%。结论:沙利度胺对各型LE皮肤损害有较好的疗效。

Objective: To observe the curative effects of thalidomide on different types of cutaneous lesions of lupus erythematosus(LE). Methods: Fifty-six patients with different types of lupus erythmatosus, including 19 cases of chronic cutaneous lupus erythematosus(CCLE), 2 cases of LE profundus(LEP), 2 cases of lupus erythmatosus-lichen planus syndrome(LE-LP), 7 cases of subacute cutaneous lupus erythmatosus(SCLE), and 26 cases of systemic lupus erythematosus (SLE) were selected to treat with thalidomide. The thalidomide was given with starting doses of 100～150 mg/d, reducing the doses gradually according to the curative effects after 2 weeks, and maintenance doses of 12.5 to 25 mg/d. The treatment courses were 6 to 8 months. Results: The cutaneous lesions of all 56 patients of lupus erythematosus were responded to thalidomide. Among those patients, 41 cases (73.2%) were cured. The incidence of relapse after drug withdrawal was 21.9% (9 of 41). Conclusion: Thalidomide has good efficacy for different types of cutaneous lesions of lupus erythematosus.